SAB Biotherapeutics (SABS) Debt Ratio (2020 - 2022)

SAB Biotherapeutics (SABS) posted Debt Ratio of 0.01 for Q4 2022, up 249.68% on a QoQ basis from 0.0 in Q4 2020.

SAB Biotherapeutics (SABS) Debt Ratio (2020 - 2022) Analysis & Trends

SAB Biotherapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.01 for Q4 2022.

Quarterly Debt Ratio changed N/A year-over-year to 0.01 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 0.01 (changed N/A YoY) and the FY2022 annual result came in at 0.01, changed N/A from the prior year.
Debt Ratio was 0.01 for Q4 2022 at SAB Biotherapeutics, up from 0.0 in the prior quarter.
Across five years, Debt Ratio topped out at 0.01 in Q4 2022 and bottomed at 0.0 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	SAB Biotherapeutics	170.64 Mn	170.64 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2022	0.01
Dec 31, 2020	0.00